Peripheral blood protein profiling in DLBCL

Published: 5 December 2020| Version 1 | DOI: 10.17632/mpgwdxsm7t.1


Quantification of 81 proteins in serum or plasma from 19 healthy blood donors and two cohorts of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to identify protein profiles associated with survival in DLBCL. The Oslo cohort comprises 51 patients, of which 18 were sampled both before and after treatment with Rituximab and chemotherapy, while the rest of the patients were only sampled before treatment. The St. Louis cohort comprises 60 patients, all of which were sampled before initiation of treatment. While EDTA plasma was sampled in the St. Louis cohort, the material obtained from healthy donors and patients in the Oslo cohort was serum. Because of this difference, data from the St. Louis cohort should not be directly compared to the data from healthy donors and Oslo cohort patients. The Normalized Protein eXpression (NPX) unit is used for all values. For this reason, values from different proteins cannot be compared. Please refer to the referenced published article for technical details, clinical information and interpretation. Data is supplied in Microsoft Excel format and as comma-separated values (CSV) files.


Steps to reproduce

Serum or plasma samples from patients or healthy blood donors were frozen, thawed and analyzed using a Proximity Extension Assay by Olink Proteomics AB, Uppsala, Sweden.


Oslo Universitetssykehus, Universitetet i Oslo


B-Cell Lymphoma